Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.
Also in this 8-page issue: Rep. James Greenwood to become president of Biotechnology Industry Association.
Medicare to cut payments for cancer drugs by 2-8%. ASCO estimates total cut in reimbursement at $500 million.
Richard Bloch, advocate for patient information services, dead at 78.
STAR completes enrollment.
NCI forms pediatric central IRB.
Funding opportunities listed.
July issue of Business & Regulatory report (8 additional pages) included.
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Joe Fraumeni, founder of molecular epidemiology, dies at 93
“It’s hard to imagine a world without the presence of this gentle scientific giant.” - Early-onset colorectal cancer is behaving like a new, biologically distinct disease, researchers note
One woman’s pregnancy shows how this distinction matters - The Directors: Directors of two Midwestern cancer centers tell us about the challenging healthcare economics in rural areas
“Institutions are feeling crunched in so many different directions” - Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- CHMP recommends approval of Opdivo + Yervoy for unresectable or advanced HCC
